US Patent Issued to Shandong Boan Biotechnology on Sept. 22 for "CLDN18.2/CD3 bispecific antibodies for the therapy of CLDN18.2-expressing solid tumors" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,742,008, issued on Sept. 22, was assigned to Shandong Boan Biotechnology Co. Ltd. (Yantai, China).

"CLDN18.2/CD3 bispecific antibodies for the therapy of CLDN18.2-expressing solid tumors" was invented by Li Zhou (Yantai, China), Avanish Varshney (Yantai, China), Deyong Song (Yantai, China), Chuangchuang Dong (Yantai, China) and Ninghai Wang (Yantai, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application provides CLDN18.2 antibodies or antigen binding fragments thereof and related CLDN18.2/CD3 bispecific antibodies, as well as corresponding nucleic acids encoding same, vectors comprising such nucleic acids, host cells transfected w...